Effects of Glucosamine on Insulin and Glucagon Secretion in Dogs and Ducks

Kajinuma, Hiroshi; Kuzuya, Tsunehiko; Ide, Takehiko; Tyler, Jean M.

doi:10.1507/endocrj1954.22.517

Cited by 8 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these studies, large amounts of glucosamine were intravenously infused into animals. [21][22][23][24][25][26][27][28][29] Under these conditions, glucosamine tended to decrease insulin secretion and/or induce insulin resistance in peripheral tissues, thus causing a rise in blood glucose levels. However, the intravenous doses used in these experimental studies were very high, ranging from 3283.2 mg/kg per day to 436363 mg/kg per day.…”

Section: Commentmentioning

confidence: 99%

The Effect of Glucosamine-Chondroitin Supplementation on Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus

Scroggie

Albright²,

Harris³

2003

Arch Intern Med

View full text Add to dashboard Cite

show abstract

Section: Commentmentioning

confidence: 99%

The Effect of Glucosamine-Chondroitin Supplementation on Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus

Scroggie

Albright²,

Harris³

2003

Arch Intern Med

View full text Add to dashboard Cite

show abstract

“…High plasma GlcN concentrations, which can only be achieved using intravenous infusions, produce insulin resistance and impair glucose tolerance in a number of species, including rats, dogs, and sheep 29–39. During the comprehensive literature search, two studies reporting the effects of GlcN infusion on glucose tolerance and insulin sensitivity in humans were identified 40,41.…”

Section: Resultsmentioning

confidence: 99%

A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals

Simon

Leeds

Anderson

2010

Diabetes Metabolism Res

View full text Add to dashboard Cite

Glucosamine (GlcN) is a widely utilized dietary supplement that is used to promote joint health. Reports that oral GlcN supplementation at usual doses adversely affects glucose metabolism in subjects with impaired glucose tolerance have raised concerns that GlcN should be contraindicated in individuals with diabetes and those at risk for developing it. This review addresses its potential, when used at typical doses, to affect glucose metabolism and insulin sensitivity in healthy individuals and those with diabetes or ‘pre-diabetes’. Publicly available scientific information and data on GlcN were systematically compiled using the electronic search tool, Dialog®, and reviewed with special emphasis on human studies. In long-term clinical trials, including those containing subjects with type 2 diabetes or ‘pre-diabetes’, GlcN produced a non-significant lowering of fasting blood glucose concentrations in all groups of subjects treated for periods of up to 3 years. Owing to limitations in study design, conclusions based on studies that report adverse affects of GlcN on insulin sensitivity and glucose tolerance in pre-diabetic subjects are suspect. However, no definitive long-term studies of GlcN use for individuals with pre-diabetes are available. Nevertheless, based on available evidence, we conclude that GlcN has no effect on fasting blood glucose levels, glucose metabolism, or insulin sensitivity at any oral dose level in healthy subjects, individuals with diabetes, or those with impaired glucose tolerance.Copyright © 2010 John Wiley & Sons, Ltd.

show abstract

“…Although it is widely known that glucose inhibits glucagon secretion from A cells in the pancreas {Foa et al 1952;Weir, Knowlton and Martin 1974;linger et al 1962;Ohneda et al 1969), the regulatory mechanism of glucose on glucagon secretion from A cells is unclear {Edwards and Taylor 1970; Muller, Faloona and linger 1971;Samols, Tyler and Marks 1972;Pagliara, Stillings, Hover, Martin and Matschinsky 1974;Matschinsky, Pagliara, Hover, Haymond and Stillings 1975;linger, Raskin, Srikant and Orci 1977). There are few reports about the effects of hexoses (MacDonald, Ball, Patel, Lauris and Steinke 1975;Hellerstrom 1967;Matschinsky and Ellerman 1968) other than glucose and their derivatives (Hahn and Ziegler 1977;Hermansen 1981;Spiro 1958;Kajinuma, Kuzuya, Ide and Tyler 1975) on glucagon secretion from these cells and the results obtained are not consistent (Hahn and Ziegler 1977;Hermansen 1981). In the present study, we investigated the effects of hexoses and their derivatives on glucagon secretion from A cells using isolated rat pancreas perfusion system.…”

Section: Discussionmentioning

confidence: 99%

Effects of Hexoses and Their Derivatives on Glucagon Secretion from Isolated Perfused Rat Pancreas

Sumida¹,

Shima²,

Shirayama³

et al. 1994

Horm Metab Res

View full text Add to dashboard Cite

Although it has been firmly established that D-glucose inhibits glucagon secretion from pancreatic A cells, the regulatory mechanism of glucagon secretion by D-glucose has not been elucidated. To study this regulatory mechanism by D-glucose, the effects of hexoses and their derivatives on glucagon secretion from the A cells of isolated perfused rat pancreas were investigated. When these cells were perfused with D-glucose, D-fructose, D-sorbitol, D-galactose, 2-deoxy-D-glucose, D-gluconic acid sodium salt and D-glucosamine HCl salt, glucagon secretion was significantly inhibited. None of the hexoses or their derivatives tested were found to stimulate glucagon secretion. The effects of these sugars on glucagon secretion were independent of their metabolism in the cells. From the findings that the sugars both metabolized and unmetabolized in the cells demonstrated comparable inhibition of glucagon secretion from the isolated perfused rat pancreas, it is speculated that the recognition system for these sugars may be probably present on the A cell membrane and responsible for mediating these inhibitory effects of glucagon secretion.

show abstract

Effects of Glucosamine on Insulin and Glucagon Secretion in Dogs and Ducks

Cited by 8 publications

References 11 publications

The Effect of Glucosamine-Chondroitin Supplementation on Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus

The Effect of Glucosamine-Chondroitin Supplementation on Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus

A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals

Effects of Hexoses and Their Derivatives on Glucagon Secretion from Isolated Perfused Rat Pancreas

Contact Info

Product

Resources

About